Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 17/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19124128 | 0.90 | ADORA3 (0.45) | ADORA3RXFP1TP53MAPTSMN1; SMN2 | |
| SCHEMBL19124234 | 0.89 | ADORA3 (0.49) | ADORA3TP53ADORA2A | |
| SCHEMBL19124375 | 0.84 | ADORA3 (0.67) | ADORA3ADORA2A | |
| SCHEMBL19125096 | 0.82 | ADORA3 (0.49) | ADORA3MAPTADORA2A | |
| SCHEMBL19124304 | 0.81 | ADORA3 (0.73) | ADORA3ADORA2A | |
| SCHEMBL19126129 | 0.80 | ADORA3 (0.45) | ADORA3MAPTSMN1; SMN2ADORA2A | |
| SCHEMBL19124327 | 0.80 | ADORA3 (0.68) | ADORA3ADORA2A | |
| SCHEMBL19125427 | 0.80 | ADORA3 (0.68) | ADORA3ADORA2A | |
| SCHEMBL19126126 | 0.79 | ADORA3 (0.48) | ADORA3MAPTADORA2A | |
| SCHEMBL19124354 | 0.77 | ADORA3 (0.48) | ADORA3MAPTADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204101-A1 | COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF | HANDOK INC. (KR) | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204101-A1 | COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885RXFP1 286/4885TP53 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.